Objectives Anti-Ro60 and anti-Ro52 autoantibodies are frequently used as diagnostic biomarkers for Sjögren’s disease, but their clinical significance in systemic lupus erythematosus (SLE) is not well characterized. Methods Patients fulfilling SLE classification criteria were studied according to their anti-Ro status. We defined Ro positivity (Ro+) as those who have either anti-Ro60 or anti-Ro52 positivity. Patient characteristics and disease outcomes, including High Disease Activity Status (HDAS) defined as an ever attainment of SLEDAI2K ≥10, adjusted mean SLEDAI (AMS), and time-adjusted mean clinical SLEDAI (excluding serologic activities) were compared using linear or logistic regressions. Furthermore, isolated or dual positivity of anti-Ro60 and anti-Ro52 were studied. Results Out of 409 patients, 47.2% were Ro+. Ro+ patients were predominantly Asian, had positive dsDNA and hypocomplementemia. They showed a higher likelihood of HDAS (OR 1.65, 95% CI 1.10–2.48, P = 0.015), AMS >4 (OR 1.84, 1.18–2.88, P = 0.007) and more frequent use of glucocorticoids (OR 1.87, 1.16–3.03, P = 0.011) and immunosuppressants (OR 2.0, 1.26–3.17, P = 0.003). Additionally, 24.4% of Ro+ patients experienced sicca symptoms, and hypergammaglobulinemia was significantly more common. Multivariate analysis confirmed that Asian ethnicity, severe flares, AMS, hypocomplementemia, rheumatoid factor, proteinuria, leucopenia and sicca symptoms were significantly linked to Ro positivity. Conclusion Anti-Ro positivity is associated with higher disease activity and increased treatment needs. Ro positivity correlates with laboratory abnormalities such as hypocomplementemia and leucopenia. These findings highlight the importance of anti-Ro60/Ro52 testing in the clinical evaluation of SLE.

中文翻译：

---

抗 Ro60 联合或不联合抗 Ro52 抗体对系统性红斑狼疮患者的影响


目的 抗 Ro60 和抗 Ro52 自身抗体常用作干燥症的诊断生物标志物，但其在系统性红斑狼疮 （SLE） 中的临床意义尚不明确。方法 根据其抗 Ro 状态研究符合 SLE 分类标准的患者。我们将 Ro 阳性 （Ro+） 定义为具有抗 Ro60 或抗 Ro52 阳性的人。使用线性或 logistic 回归比较患者特征和疾病结局，包括定义为始终达到 SLEDAI2K ≥10 的高疾病活动状态 （HDAS）、调整后的平均 SLEDAI （AMS） 和时间调整的平均临床 SLEDAI（不包括血清学活动）。此外，研究了抗 Ro60 和抗 Ro52 的孤立或双重阳性。结果 在 409 例患者中，47.2% 为 Ro+。Ro+ 患者以亚洲人为主，dsDNA 阳性和低补体血症。他们显示 HDAS （OR 1.65， 95% CI 1.10-2.48， P = 0.015）、AMS >4 （OR 1.84， 1.18-2.88， P = 0.007） 的可能性更高，并且更频繁地使用糖皮质激素 （OR 1.87， 1.16-3.03， P = 0.011） 和免疫抑制剂 （OR 2.0， 1.26-3.17，P = 0.003）。此外，24.4% 的 Ro+ 患者出现干燥症状，高丙种球蛋白血症明显更常见。多因素分析证实，亚洲人种、严重发作、AMS、低补体血症、类风湿因子、蛋白尿、白细胞减少和干燥症状与 Ro 阳性显著相关。结论 抗 Ro 阳性与较高的疾病活动度和增加的治疗需求相关。Ro 阳性与实验室异常相关，例如低补体血症和白细胞减少症。这些发现强调了抗 Ro60/Ro52 检测在 SLE 临床评估中的重要性。